25 XP   0   0   10

Karyopharm Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Karyopharm together

PenkeI guess you are interested in Karyopharm Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Karyopharm Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Karyopharm Therapeutics Inc

I send you an email if I find something interesting about Karyopharm Therapeutics Inc.

Quick analysis of Karyopharm (30 sec.)










What can you expect buying and holding a share of Karyopharm? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$-1.18
Expected worth in 1 year
$-2.22
How sure are you?
22.5%

+ What do you gain per year?

Total Gains per Share
$-1.04
Return On Investment
-91.9%

For what price can you sell your share?

Current Price per Share
$1.13
Expected price per share
$0.9706 - $1.7
How sure are you?
50%

1. Valuation of Karyopharm (5 min.)




Live pricePrice per Share (EOD)

$1.13

Intrinsic Value Per Share

$-8.68 - $-2.80

Total Value Per Share

$-9.87 - $-3.99

2. Growth of Karyopharm (5 min.)




Is Karyopharm growing?

Current yearPrevious yearGrowGrow %
How rich?-$136.2m-$89m$832.2k0.9%

How much money is Karyopharm making?

Current yearPrevious yearGrowGrow %
Making money-$35.7m-$41.3m$5.5m15.5%
Net Profit Margin-98.7%-106.4%--

How much money comes from the company's main activities?

3. Financial Health of Karyopharm (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#997 / 1011

Most Revenue
#179 / 1011

Most Profit
#834 / 1011

Most Efficient
#567 / 1011

What can you expect buying and holding a share of Karyopharm? (5 min.)

Welcome investor! Karyopharm's management wants to use your money to grow the business. In return you get a share of Karyopharm.

What can you expect buying and holding a share of Karyopharm?

First you should know what it really means to hold a share of Karyopharm. And how you can make/lose money.

Speculation

The Price per Share of Karyopharm is $1.13. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Karyopharm.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Karyopharm, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-1.18. Based on the TTM, the Book Value Change Per Share is $-0.26 per quarter. Based on the YOY, the Book Value Change Per Share is $0.14 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Karyopharm.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.36-32.2%-0.31-27.5%-0.36-31.8%-0.36-31.9%-0.31-27.7%
Usd Book Value Change Per Share-0.31-27.5%-0.26-23.0%0.1412.1%-0.14-12.3%-0.06-5.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.31-27.5%-0.26-23.0%0.1412.1%-0.14-12.3%-0.06-5.6%
Usd Price Per Share0.87-1.97-5.19-8.53-13.40-
Price to Earnings Ratio-0.59--1.64--3.66--4.76--13.25-
Price-to-Total Gains Ratio-2.78--7.92--71.92--39.34--56.65-
Price to Book Ratio-0.73--3.77--10.66-2.25-7.22-
Price-to-Total Gains Ratio-2.78--7.92--71.92--39.34--56.65-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.13
Number of shares884
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.26-0.14
Usd Total Gains Per Share-0.26-0.14
Gains per Quarter (884 shares)-229.61-122.68
Gains per Year (884 shares)-918.44-490.72
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-918-9280-491-501
20-1837-18460-981-992
30-2755-27640-1472-1483
40-3674-36820-1963-1974
50-4592-46000-2454-2465
60-5511-55180-2944-2956
70-6429-64360-3435-3447
80-7348-73540-3926-3938
90-8266-82720-4416-4429
100-9184-91900-4907-4920

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%1.019.00.05.0%1.039.00.02.5%1.045.01.02.1%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%3.017.00.015.0%9.031.00.022.5%12.033.02.025.5%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.047.00.0%
Total Gains per Share0.04.00.00.0%2.010.00.016.7%3.017.00.015.0%9.031.00.022.5%12.033.02.025.5%

Fundamentals of Karyopharm

About Karyopharm Therapeutics Inc

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Fundamental data was last updated by Penke on 2024-04-11 12:47:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Karyopharm Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Karyopharm earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Karyopharm to the Biotechnology industry mean.
  • A Net Profit Margin of -124.0% means that $-1.24 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Karyopharm Therapeutics Inc:

  • The MRQ is -124.0%. The company is making a huge loss. -2
  • The TTM is -98.7%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-124.0%TTM-98.7%-25.3%
TTM-98.7%YOY-106.4%+7.7%
TTM-98.7%5Y-2,297.1%+2,198.4%
5Y-2,297.1%10Y-77,660.6%+75,363.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-124.0%-200.1%+76.1%
TTM-98.7%-216.8%+118.1%
YOY-106.4%-288.3%+181.9%
5Y-2,297.1%-449.1%-1,848.0%
10Y-77,660.6%-605.5%-77,055.1%
1.1.2. Return on Assets

Shows how efficient Karyopharm is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Karyopharm to the Biotechnology industry mean.
  • -17.4% Return on Assets means that Karyopharm generated $-0.17 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Karyopharm Therapeutics Inc:

  • The MRQ is -17.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -12.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-17.4%TTM-12.9%-4.5%
TTM-12.9%YOY-14.9%+2.0%
TTM-12.9%5Y-14.2%+1.3%
5Y-14.2%10Y-14.7%+0.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-17.4%-13.3%-4.1%
TTM-12.9%-12.8%-0.1%
YOY-14.9%-11.7%-3.2%
5Y-14.2%-13.9%-0.3%
10Y-14.7%-15.7%+1.0%
1.1.3. Return on Equity

Shows how efficient Karyopharm is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Karyopharm to the Biotechnology industry mean.
  • 0.0% Return on Equity means Karyopharm generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Karyopharm Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-24.6%+24.6%
5Y-24.6%10Y-21.5%-3.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--16.9%+16.9%
TTM--16.1%+16.1%
YOY--15.1%+15.1%
5Y-24.6%-19.3%-5.3%
10Y-21.5%-20.2%-1.3%

1.2. Operating Efficiency of Karyopharm Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Karyopharm is operating .

  • Measures how much profit Karyopharm makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Karyopharm to the Biotechnology industry mean.
  • An Operating Margin of -112.0% means the company generated $-1.12  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Karyopharm Therapeutics Inc:

  • The MRQ is -112.0%. The company is operating very inefficient. -2
  • The TTM is -87.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-112.0%TTM-87.4%-24.6%
TTM-87.4%YOY-91.7%+4.3%
TTM-87.4%5Y-2,181.4%+2,093.9%
5Y-2,181.4%10Y-78,456.0%+76,274.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-112.0%-296.2%+184.2%
TTM-87.4%-232.5%+145.1%
YOY-91.7%-298.2%+206.5%
5Y-2,181.4%-492.1%-1,689.3%
10Y-78,456.0%-632.4%-77,823.6%
1.2.2. Operating Ratio

Measures how efficient Karyopharm is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 2.12 means that the operating costs are $2.12 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Karyopharm Therapeutics Inc:

  • The MRQ is 2.120. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.893. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.120TTM1.893+0.227
TTM1.893YOY1.917-0.024
TTM1.8935Y35.798-33.904
5Y35.79810Y1,516.559-1,480.762
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.1203.231-1.111
TTM1.8933.310-1.417
YOY1.9173.890-1.973
5Y35.7985.739+30.059
10Y1,516.5597.876+1,508.683

1.3. Liquidity of Karyopharm Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Karyopharm is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.37 means the company has $3.37 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Karyopharm Therapeutics Inc:

  • The MRQ is 3.367. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.280. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.367TTM4.280-0.913
TTM4.280YOY3.969+0.310
TTM4.2805Y53.453-49.174
5Y53.45310Y32.902+20.551
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.3673.890-0.523
TTM4.2804.173+0.107
YOY3.9695.344-1.375
5Y53.4536.126+47.327
10Y32.9026.448+26.454
1.3.2. Quick Ratio

Measures if Karyopharm is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Karyopharm to the Biotechnology industry mean.
  • A Quick Ratio of 5.16 means the company can pay off $5.16 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Karyopharm Therapeutics Inc:

  • The MRQ is 5.157. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 6.663. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ5.157TTM6.663-1.507
TTM6.663YOY4.993+1.670
TTM6.6635Y82.464-75.800
5Y82.46410Y49.815+32.649
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.1573.514+1.643
TTM6.6633.998+2.665
YOY4.9935.380-0.387
5Y82.4646.105+76.359
10Y49.8156.404+43.411

1.4. Solvency of Karyopharm Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Karyopharm assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Karyopharm to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.57 means that Karyopharm assets are financed with 156.6% credit (debt) and the remaining percentage (100% - 156.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Karyopharm Therapeutics Inc:

  • The MRQ is 1.566. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.329. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ1.566TTM1.329+0.237
TTM1.329YOY1.347-0.018
TTM1.3295Y1.080+0.249
5Y1.08010Y0.606+0.474
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5660.339+1.227
TTM1.3290.336+0.993
YOY1.3470.271+1.076
5Y1.0800.366+0.714
10Y0.6060.389+0.217
1.4.2. Debt to Equity Ratio

Measures if Karyopharm is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Karyopharm to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Karyopharm Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y1.191-1.191
5Y1.19110Y0.684+0.507
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.388-0.388
TTM-0.402-0.402
YOY-0.335-0.335
5Y1.1910.426+0.765
10Y0.6840.461+0.223

2. Market Valuation of Karyopharm Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Karyopharm generates.

  • Above 15 is considered overpriced but always compare Karyopharm to the Biotechnology industry mean.
  • A PE ratio of -0.59 means the investor is paying $-0.59 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Karyopharm Therapeutics Inc:

  • The EOD is -0.777. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.595. Based on the earnings, the company is expensive. -2
  • The TTM is -1.642. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.777MRQ-0.595-0.182
MRQ-0.595TTM-1.642+1.047
TTM-1.642YOY-3.657+2.015
TTM-1.6425Y-4.764+3.122
5Y-4.76410Y-13.247+8.483
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.777-2.264+1.487
MRQ-0.595-2.629+2.034
TTM-1.642-2.680+1.038
YOY-3.657-4.145+0.488
5Y-4.764-6.257+1.493
10Y-13.247-6.254-6.993
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Karyopharm Therapeutics Inc:

  • The EOD is -1.749. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.339. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.641. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.749MRQ-1.339-0.410
MRQ-1.339TTM-2.641+1.303
TTM-2.641YOY-4.111+1.469
TTM-2.6415Y-5.754+3.112
5Y-5.75410Y-18.167+12.413
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.749-2.973+1.224
MRQ-1.339-3.333+1.994
TTM-2.641-3.553+0.912
YOY-4.111-5.605+1.494
5Y-5.754-8.376+2.622
10Y-18.167-8.865-9.302
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Karyopharm is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -0.73 means the investor is paying $-0.73 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Karyopharm Therapeutics Inc:

  • The EOD is -0.955. Based on the equity, the company is expensive. -2
  • The MRQ is -0.731. Based on the equity, the company is expensive. -2
  • The TTM is -3.767. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.955MRQ-0.731-0.224
MRQ-0.731TTM-3.767+3.036
TTM-3.767YOY-10.659+6.892
TTM-3.7675Y2.248-6.015
5Y2.24810Y7.217-4.969
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.9551.896-2.851
MRQ-0.7312.115-2.846
TTM-3.7672.093-5.860
YOY-10.6592.884-13.543
5Y2.2483.542-1.294
10Y7.2173.916+3.301
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Karyopharm Therapeutics Inc.

3.1. Institutions holding Karyopharm Therapeutics Inc

Institutions are holding 68.36% of the shares of Karyopharm Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31BlackRock Inc8.75290.000210071677-1014856-9.154
2023-12-31Vanguard Group Inc7.56960.00028710158-109771-1.2446
2023-12-31Avidity Partners Management LP7.21190.2616829857000
2023-12-31Palo Alto Investors, LLC4.43410.39765102193-573683-10.1074
2023-09-30Citadel Advisors Llc2.69750.00093103888-45794-1.4539
2023-12-31Goldman Sachs Group Inc2.25360.0002259318667813935.4111
2023-12-31Geode Capital Management, LLC2.07050.00022382428952824.166
2023-09-30Jacobs Levy Equity Management, Inc.2.04540.018723535281676673247.7152
2023-12-31GSA Capital Partners LLP2.03180.1723379851769687311.4012
2023-12-31State Street Corporation1.78480.00012053773107680.5271
2023-12-31Renaissance Technologies Corp1.70720.002619643771233977168.9454
2023-12-31Marshall Wace Asset Management Ltd1.67450.00281926782-256419-11.7451
2023-12-31BNP Paribas Arbitrage, SA1.53750.001717691841082866.5197
2023-12-31Adage Capital Partners Gp LLC1.44550.003166330016633000
2023-12-31Millennium Management LLC1.33340.0006153426441635637.2442
2023-12-31CAM Group Holding A/S1.30360.0174150000000
2023-12-31Deutsche Bank AG1.15320.0006132700812687772178.8686
2023-12-31JPMorgan Chase & Co1.02650.00011181120399943.5048
2023-12-31AlphaCentric Advisors, LLC0.97770.6532112500000
2023-12-31Tejara Capital Ltd0.89630.37371031348-46040-4.2733
Total 53.90751.905462029769+6914676+11.1%

3.2. Funds holding Karyopharm Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv2.7890.0002320924900
2024-03-28iShares Russell 2000 ETF2.38550.0063274496013230.0482
2023-12-31Vanguard Explorer Inv1.9660.0092226224300
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.42790.00191642989746274.7583
2024-03-31C WorldWide Healthcare Select 1A1.30360.2709150000000
2023-12-31AlphaCentric LifeSci Healthcare I0.97770.9336112500000
2024-01-31Fidelity Small Cap Index0.97320.00341119782272182.4912
2024-03-28iShares Russell 2000 Growth ETF0.85490.0128983668-1144-0.1162
2023-12-31Vanguard VIF Small Co Gr0.69980.046180528300
2024-02-29BlackRock Advantage Small Cap Core Instl0.61010.0232702009-42868-5.755
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.58430.001967232498001.4792
2024-02-29Fidelity Extended Market Index0.54960.0019632383-3064-0.4822
2024-02-29Xtrackers S&P 500 Swap ETF 1C0.48330.007155608100
2023-12-31Candriam Global Equities Oncology0.46110.0247530630-610000-53.4792
2024-02-29Delaware Healthcare I0.43450.074450000012000031.5789
2024-02-29Vanguard Russell 2000 ETF0.34650.0049398701322978.8146
2023-12-31NT R2000 Growth Index Fund - NL0.29550.00834000100
2024-03-31State St Russell Sm Cap® Indx SL Cl I0.28740.005133074000
2023-12-31NT R2000 Index Fund - NL0.28340.00393260985590.1717
2024-03-31BlackRock Extended Equity Market K0.27030.00323110201120.036
Total 17.98361.442720693161-391140-1.9%

3.3. Insider Transactions

Insiders are holding 6.063% of the shares of Karyopharm Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-04-04Richard A PaulsonSELL35631.29
2024-03-05Richard A PaulsonSELL35731.3
2024-02-29Michael ManoSELL169731.17
2024-02-29Michael MasonSELL276871.17
2024-02-29Reshma RangwalaSELL156671.17
2024-02-29Richard A PaulsonSELL804701.17
2024-02-27Michael MasonSELL25451.32
2024-02-15Stuart PoultonSELL58471.33
2024-02-06Michael MasonSELL42051.59
2024-02-06Richard A PaulsonSELL40121.59
2024-01-04Richard A PaulsonSELL41140.82
2023-12-04Richard A PaulsonSELL36220.79
2023-11-06Richard A PaulsonSELL36060.92
2023-10-04Richard A PaulsonSELL35891.27
2023-09-12Garen G BohlinBUY411401.22
2023-09-01Michael ManoSELL38881.33
2023-09-01Michael MasonSELL69131.33
2023-09-01Sohanya Roshan ChengSELL74151.33
2023-08-07Richard A PaulsonSELL37221.72
2023-07-28Stuart PoultonSELL28451.7

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Karyopharm Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.311-0.260-17%0.137-327%-0.139-55%-0.063-80%
Book Value Per Share---1.184-0.767-35%-0.774-35%-0.128-89%0.708-267%
Current Ratio--3.3674.280-21%3.969-15%53.453-94%32.902-90%
Debt To Asset Ratio--1.5661.329+18%1.347+16%1.080+45%0.606+158%
Debt To Equity Ratio----0%-0%1.191-100%0.684-100%
Dividend Per Share----0%-0%-0%-0%
Eps---0.364-0.311-14%-0.359-1%-0.360-1%-0.313-14%
Free Cash Flow Per Share---0.162-0.201+25%-0.325+101%-0.305+89%-0.254+57%
Free Cash Flow To Equity Per Share---0.159-0.115-28%0.096-266%-0.042-73%0.018-997%
Gross Profit Margin--1.0001.0000%1.0000%1.0040%1.0020%
Intrinsic Value_10Y_max---2.805--------
Intrinsic Value_10Y_min---8.683--------
Intrinsic Value_1Y_max---0.908--------
Intrinsic Value_1Y_min---0.999--------
Intrinsic Value_3Y_max---2.251--------
Intrinsic Value_3Y_min---2.907--------
Intrinsic Value_5Y_max---3.018--------
Intrinsic Value_5Y_min---4.698--------
Market Cap130025710.000+23%99532955.000226825823.750-56%596622395.000-83%981320142.750-90%1541940950.125-94%
Net Profit Margin---1.240-0.987-20%-1.064-14%-22.971+1753%-776.606+62543%
Operating Margin---1.120-0.874-22%-0.917-18%-21.814+1847%-784.560+69929%
Operating Ratio--2.1201.893+12%1.917+11%35.798-94%1516.559-100%
Pb Ratio-0.955-31%-0.731-3.767+415%-10.659+1359%2.248-133%7.217-110%
Pe Ratio-0.777-31%-0.595-1.642+176%-3.657+515%-4.764+701%-13.247+2127%
Price Per Share1.130+23%0.8651.971-56%5.185-83%8.528-90%13.400-94%
Price To Free Cash Flow Ratio-1.749-31%-1.339-2.641+97%-4.111+207%-5.754+330%-18.167+1257%
Price To Total Gains Ratio-3.631-31%-2.779-7.916+185%-71.916+2487%-39.343+1315%-56.648+1938%
Quick Ratio--5.1576.663-23%4.993+3%82.464-94%49.815-90%
Return On Assets---0.174-0.129-26%-0.149-14%-0.142-18%-0.147-16%
Return On Equity----0%-0%-0.2460%-0.2150%
Total Gains Per Share---0.311-0.260-17%0.137-327%-0.139-55%-0.063-80%
Usd Book Value---136206000.000-88256000.000-35%-89088250.000-35%-14707000.000-89%81419775.000-267%
Usd Book Value Change Per Share---0.311-0.260-17%0.137-327%-0.139-55%-0.063-80%
Usd Book Value Per Share---1.184-0.767-35%-0.774-35%-0.128-89%0.708-267%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.364-0.311-14%-0.359-1%-0.360-1%-0.313-14%
Usd Free Cash Flow---18585000.000-23180750.000+25%-37418000.000+101%-35056500.000+89%-29264400.000+57%
Usd Free Cash Flow Per Share---0.162-0.201+25%-0.325+101%-0.305+89%-0.254+57%
Usd Free Cash Flow To Equity Per Share---0.159-0.115-28%0.096-266%-0.042-73%0.018-997%
Usd Market Cap130025710.000+23%99532955.000226825823.750-56%596622395.000-83%981320142.750-90%1541940950.125-94%
Usd Price Per Share1.130+23%0.8651.971-56%5.185-83%8.528-90%13.400-94%
Usd Profit---41837000.000-35774750.000-14%-41322750.000-1%-41417050.000-1%-35981675.000-14%
Usd Revenue--33747000.00036508250.000-8%39268500.000-14%33095200.000+2%17363025.000+94%
Usd Total Gains Per Share---0.311-0.260-17%0.137-327%-0.139-55%-0.063-80%
 EOD+6 -2MRQTTM+5 -26YOY+6 -255Y+11 -2210Y+11 -22

4.2. Fundamental Score

Let's check the fundamental score of Karyopharm Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.777
Price to Book Ratio (EOD)Between0-1-0.955
Net Profit Margin (MRQ)Greater than0-1.240
Operating Margin (MRQ)Greater than0-1.120
Quick Ratio (MRQ)Greater than15.157
Current Ratio (MRQ)Greater than13.367
Debt to Asset Ratio (MRQ)Less than11.566
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.174
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Karyopharm Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.064
Ma 20Greater thanMa 501.323
Ma 50Greater thanMa 1001.335
Ma 100Greater thanMa 2001.105
OpenGreater thanClose1.170
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets240,438
Total Liabilities376,644
Total Stockholder Equity-136,206
 As reported
Total Liabilities 376,644
Total Stockholder Equity+ -136,206
Total Assets = 240,438

Assets

Total Assets240,438
Total Current Assets233,921
Long-term Assets6,517
Total Current Assets
Cash And Cash Equivalents 52,891
Short-term Investments 139,212
Net Receivables 26,962
Inventory 3,043
Other Current Assets 11,813
Total Current Assets  (as reported)233,921
Total Current Assets  (calculated)233,921
+/-0
Long-term Assets
Property Plant Equipment 4,882
Long-term Assets Other 1,334
Long-term Assets  (as reported)6,517
Long-term Assets  (calculated)6,216
+/- 301

Liabilities & Shareholders' Equity

Total Current Liabilities69,479
Long-term Liabilities307,165
Total Stockholder Equity-136,206
Total Current Liabilities
Short-term Debt 3,308
Accounts payable 3,123
Other Current Liabilities 63,048
Total Current Liabilities  (as reported)69,479
Total Current Liabilities  (calculated)69,479
+/-0
Long-term Liabilities
Long term Debt 170,919
Capital Lease Obligations 6,097
Long-term Liabilities Other 978
Long-term Liabilities  (as reported)307,165
Long-term Liabilities  (calculated)177,994
+/- 129,171
Total Stockholder Equity
Common Stock12
Retained Earnings -1,487,038
Accumulated Other Comprehensive Income -161
Other Stockholders Equity 1,350,981
Total Stockholder Equity (as reported)-136,206
Total Stockholder Equity (calculated)-136,206
+/-0
Other
Capital Stock12
Cash and Short Term Investments 192,103
Common Stock Shares Outstanding 114,778
Liabilities and Stockholders Equity 240,438
Net Debt 124,125
Net Invested Capital 34,713
Net Working Capital 164,442
Property Plant and Equipment Gross 11,447
Short Long Term Debt Total 177,016



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302011-12-31
> Total Assets 
7,224
0
1,311
0
62,477
55,904
158,226
149,285
137,679
235,155
220,337
292,040
263,293
236,971
215,443
192,135
170,897
183,623
180,385
155,435
185,750
163,773
180,294
146,373
256,589
219,992
341,192
287,214
238,100
297,745
294,963
416,141
380,011
337,587
313,050
274,909
286,567
254,094
305,305
294,033
256,478
231,236
358,172
325,800
297,830
269,960
240,438
240,438269,960297,830325,800358,172231,236256,478294,033305,305254,094286,567274,909313,050337,587380,011416,141294,963297,745238,100287,214341,192219,992256,589146,373180,294163,773185,750155,435180,385183,623170,897192,135215,443236,971263,293292,040220,337235,155137,679149,285158,22655,90462,47701,31107,224
   > Total Current Assets 
0
0
954
0
62,189
53,586
157,956
147,566
135,283
231,346
207,751
249,319
225,252
198,344
177,600
138,142
124,200
130,251
131,636
112,230
145,724
121,682
148,423
133,313
244,559
211,562
334,612
271,435
222,830
280,867
273,665
370,920
317,836
285,447
289,539
255,511
273,502
241,579
258,098
276,533
242,447
177,533
326,750
297,064
291,381
247,164
233,921
233,921247,164291,381297,064326,750177,533242,447276,533258,098241,579273,502255,511289,539285,447317,836370,920273,665280,867222,830271,435334,612211,562244,559133,313148,423121,682145,724112,230131,636130,251124,200138,142177,600198,344225,252249,319207,751231,346135,283147,566157,95653,58662,189095400
       Cash And Cash Equivalents 
6,512
0
391
0
61,667
52,928
155,974
144,893
132,307
227,131
150,609
51,453
24,231
43,499
58,358
42,188
37,717
43,908
49,663
25,577
55,381
54,450
68,997
37,499
118,966
101,600
118,021
83,506
75,545
168,004
128,858
202,247
103,102
82,301
85,918
88,471
141,309
137,400
190,459
153,256
82,248
71,351
135,188
84,062
80,894
43,655
52,891
52,89143,65580,89484,062135,18871,35182,248153,256190,459137,400141,30988,47185,91882,301103,102202,247128,858168,00475,54583,506118,021101,600118,96637,49968,99754,45055,38125,57749,66343,90837,71742,18858,35843,49924,23151,453150,609227,131132,307144,893155,97452,92861,667039106,512
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
55,115
194,956
196,955
151,738
117,275
94,228
85,019
82,903
79,889
84,307
88,073
64,956
77,472
93,418
122,155
105,170
210,178
180,918
141,614
99,525
133,098
149,884
193,615
180,743
163,322
135,894
94,581
66,812
38,156
52,055
88,598
77,030
142,779
176,322
155,871
164,660
139,212
139,212164,660155,871176,322142,77977,03088,59852,05538,15666,81294,581135,894163,322180,743193,615149,884133,09899,525141,614180,918210,178105,170122,15593,41877,47264,95688,07384,30779,88982,90385,01994,228117,275151,738196,955194,95655,1150000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,928
7,862
9,281
9,581
11,062
12,881
17,843
17,887
18,752
22,497
24,992
23,479
27,446
47,086
35,200
32,280
37,923
26,962
26,96237,92332,28035,20047,08627,44623,47924,99222,49718,75217,88717,84312,88111,0629,5819,2817,8627,92800000000000000000000000000000
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
100
346
970
1,652
2,011
2,644
3,114
3,905
3,943
4,106
3,874
3,470
4,249
4,224
3,827
3,672
3,105
3,043
3,0433,1053,6723,8274,2244,2493,4703,8744,1063,9433,9053,1142,6442,0111,65297034610000000000000000000000000000000
   > Long-term Assets 
0
0
357
0
288
2,318
270
1,719
2,396
3,809
12,586
42,721
38,041
38,627
37,843
53,993
46,697
53,372
48,749
43,205
40,026
42,091
31,871
13,060
12,030
8,430
6,580
15,779
15,270
16,878
21,298
45,221
62,175
52,140
23,511
19,398
13,065
12,515
47,207
17,500
14,031
53,703
31,422
28,736
6,449
22,796
6,517
6,51722,7966,44928,73631,42253,70314,03117,50047,20712,51513,06519,39823,51152,14062,17545,22121,29816,87815,27015,7796,5808,43012,03013,06031,87142,09140,02643,20548,74953,37246,69753,99337,84338,62738,04142,72112,5863,8092,3961,7192702,318288035700
       Property Plant Equipment 
328
0
327
0
258
246
240
322
604
2,734
2,754
3,282
3,234
3,660
3,483
3,343
3,170
2,991
2,836
2,654
2,473
2,304
2,185
2,454
2,611
2,914
3,863
15,065
14,555
14,144
3,046
13,134
12,605
12,051
2,219
11,004
10,420
9,871
1,642
9,062
8,502
7,933
7,377
6,625
6,062
5,482
4,882
4,8825,4826,0626,6257,3777,9338,5029,0621,6429,87110,42011,0042,21912,05112,60513,1343,04614,14414,55515,0653,8632,9142,6112,4542,1852,3042,4732,6542,8362,9913,1703,3433,4833,6603,2343,2822,7542,73460432224024625803270328
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
8,658
38,539
34,407
34,430
33,878
50,165
42,933
49,598
45,434
40,257
37,269
39,498
29,396
10,314
8,781
4,804
2,001
0
0
2,022
2,016
31,373
48,856
39,371
24,215
7,676
2,006
2,005
0
0
0
0
0
0
0
0
0
0000000002,0052,0067,67624,21539,37148,85631,3732,0162,022002,0014,8048,78110,31429,39639,49837,26940,25745,43449,59842,93350,16533,87834,43034,40738,5398,6580000000000
       Long-term Assets Other 
0
0
30
0
30
2,072
30
1,397
1,792
1,075
1,174
900
400
537
482
485
594
783
479
294
284
289
290
292
638
712
716
714
715
712
16,236
714
714
718
-2,923
718
639
639
45,565
8,438
4,898
45,144
23,412
21,477
387
16,933
1,334
1,33416,93338721,47723,41245,1444,8988,43845,565639639718-2,92371871471416,2367127157147167126382922902892842944797835944854825374009001,1741,0751,7921,397302,0723003000
> Total Liabilities 
2,117
0
29,188
0
2,541
103,688
3,292
5,185
5,999
7,351
13,543
16,515
15,966
16,379
17,078
15,099
17,331
16,691
18,142
17,072
19,036
22,596
50,830
50,844
43,117
48,914
158,022
165,930
155,631
237,875
245,189
249,994
250,212
253,817
262,504
314,549
369,699
380,071
384,978
377,112
372,816
371,516
374,828
370,974
369,078
370,356
376,644
376,644370,356369,078370,974374,828371,516372,816377,112384,978380,071369,699314,549262,504253,817250,212249,994245,189237,875155,631165,930158,02248,91443,11750,84450,83022,59619,03617,07218,14216,69117,33115,09917,07816,37915,96616,51513,5437,3515,9995,1853,292103,6882,541029,18802,117
   > Total Current Liabilities 
2,117
0
1,930
0
2,541
3,996
3,292
5,015
5,647
6,234
12,301
14,702
14,099
14,440
15,132
13,222
15,523
14,952
16,476
15,481
17,520
21,155
49,467
46,734
36,544
41,567
46,904
43,860
32,174
39,202
46,350
49,699
50,570
52,630
297
62,008
58,123
68,866
73,718
66,337
62,541
61,761
65,908
61,555
58,928
62,079
69,479
69,47962,07958,92861,55565,90861,76162,54166,33773,71868,86658,12362,00829752,63050,57049,69946,35039,20232,17443,86046,90441,56736,54446,73449,46721,15517,52015,48116,47614,95215,52313,22215,13214,44014,09914,70212,3016,2345,6475,0153,2923,9962,54101,93002,117
       Short-term Debt 
0
0
764
0
0
0
1,168
1,550
2,025
3,791
0
0
0
0
0
0
0
0
0
0
13,168
18,013
21,748
21,723
23,158
29,411
32,883
1,375
1,522
1,583
1,646
1,711
1,778
1,847
1,917
1,997
2,079
2,163
2,316
2,463
2,615
2,770
2,872
2,977
3,084
3,195
3,308
3,3083,1953,0842,9772,8722,7702,6152,4632,3162,1632,0791,9971,9171,8471,7781,7111,6461,5831,5221,37532,88329,41123,15821,72321,74818,01313,16800000000003,7912,0251,5501,16800076400
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,375
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000001,375000000000000000000000000000
       Accounts payable 
1,142
0
1,076
0
1,728
1,749
1,740
3,273
3,456
2,102
6,288
6,957
4,469
4,568
3,808
4,109
4,063
2,193
4,751
4,245
3,247
1,890
5,665
4,949
3,794
2,238
4,332
2,266
1,113
3,068
985
1,694
1,888
2,422
4,450
3,040
2,309
881
1,603
3,440
1,694
813
2,773
9,045
2,287
943
3,123
3,1239432,2879,0452,7738131,6943,4401,6038812,3093,0404,4502,4221,8881,6949853,0681,1132,2664,3322,2383,7944,9495,6651,8903,2474,2454,7512,1934,0634,1093,8084,5684,4696,9576,2882,1023,4563,2731,7401,7491,72801,07601,142
       Other Current Liabilities 
975
0
24
0
813
2,247
305
135
130
327
6,013
7,745
9,630
9,872
11,324
9,113
11,460
12,759
11,725
11,236
80
202
133
333
229
556
327
29,569
28,252
33,498
41,378
45,007
46,607
48,064
-6,367
1,360
524
1,124
678
60,434
58,232
58,178
60,263
49,533
1,749
57,941
63,048
63,04857,9411,74949,53360,26358,17858,23260,4346781,1245241,360-6,36748,06446,60745,00741,37833,49828,25229,5693275562293331332028011,23611,72512,75911,4609,11311,3249,8729,6307,7456,0133271301353052,2478130240975
   > Long-term Liabilities 
0
0
27,258
0
1,728
99,692
1,819
170
352
1,117
1,242
1,813
1,867
1,939
1,946
1,877
1,808
1,739
1,666
1,591
1,516
1,441
1,363
4,110
6,573
7,347
111,118
122,070
123,457
198,673
245,189
200,295
199,642
201,187
262,207
252,541
311,576
311,205
384,978
310,775
310,275
371,516
374,828
370,974
310,150
370,356
307,165
307,165370,356310,150370,974374,828371,516310,275310,775384,978311,205311,576252,541262,207201,187199,642200,295245,189198,673123,457122,070111,1187,3476,5734,1101,3631,4411,5161,5911,6661,7391,8081,8771,9461,9391,8671,8131,2421,1173521701,81999,6921,728027,25800
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
102,664
104,368
106,157
107,962
109,857
111,769
113,776
115,802
117,928
0
168,899
169,094
0
169,491
169,693
169,894
0
170,306
0
0
0
000170,3060169,894169,693169,4910169,094168,8990117,928115,802113,776111,769109,857107,962106,157104,368102,66400000000000000000000000000
       Warrants
0
0
0
0
0
199,384
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000000000199,38400000
       Other Liabilities 
0
0
0
0
0
0
0
170
352
1,117
1,242
1,813
1,867
1,939
1,946
1,877
1,808
1,739
1,666
1,591
1,516
1,441
1,363
4,110
6,573
7,347
8,454
3,245
3,245
77,068
75,780
75,780
73,588
73,588
144,576
145,845
132,478
210,977
215,685
74,623
70,125
0
0
0
0
0
0
00000070,12574,623215,685210,977132,478145,845144,57673,58873,58875,78075,78077,0683,2453,2458,4547,3476,5734,1101,3631,4411,5161,5911,6661,7391,8081,8771,9461,9391,8671,8131,2421,1173521700000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
201
1,117
1,242
1,813
1,867
1,939
1,946
1,877
1,808
1,739
1,666
1,591
1,516
1,441
1,363
4,110
6,573
7,347
8,454
3,245
3,245
3,479
2,192
2,192
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000002,1922,1923,4793,2453,2458,4547,3476,5734,1101,3631,4411,5161,5911,6661,7391,8081,8771,9461,9391,8671,8131,2421,11720100000000
> Total Stockholder Equity
5,107
0
-27,877
0
59,936
-47,784
154,934
144,100
131,680
227,804
206,794
275,525
247,327
220,592
198,365
177,036
153,566
166,932
162,243
138,363
166,714
141,177
129,464
95,529
213,472
171,078
183,170
121,284
82,469
59,870
49,774
166,147
129,799
83,770
50,546
-39,640
-83,132
-125,977
-79,673
-83,079
-116,338
-140,280
-16,656
-45,174
-71,248
-100,396
-136,206
-136,206-100,396-71,248-45,174-16,656-140,280-116,338-83,079-79,673-125,977-83,132-39,64050,54683,770129,799166,14749,77459,87082,469121,284183,170171,078213,47295,529129,464141,177166,714138,363162,243166,932153,566177,036198,365220,592247,327275,525206,794227,804131,680144,100154,934-47,78459,9360-27,87705,107
   Common Stock
0
0
0
0
2
-20,778
3
3
3
3
3
4
4
4
4
4
4
4
4
4
5
5
5
5
6
6
6
6
6
6
7
7
7
7
7
8
8
8
8
8
8
8
12
12
12
12
12
1212121212888888877777666666555544444444433333-20,77820000
   Retained Earnings Total Equity000-1,378,065-1,343,939-1,305,433-1,269,109-1,220,047-1,178,648-1,217,368-1,165,556-1,111,974-1,069,611-1,026,190-972,695-926,269-873,338-824,691-783,324-739,909-673,748-615,538-567,454-533,800-495,341-456,300-425,660-396,275-366,104-339,169-313,744-283,586-256,527-227,481-197,108-164,412-138,346-112,418-92,694-76,263-62,569-50,42300000
   Accumulated Other Comprehensive Income 
0
0
-206
0
-275
-312
-350
-393
-435
-363
-29
19
-143
-26
-282
94
138
-28
-274
-204
-165
-90
-217
-286
-260
-153
-244
-28
61
-30
-37
-420
891
603
518
301
196
372
191
87
-538
-752
-638
-419
-783
-742
-161
-161-742-783-419-638-752-53887191372196301518603891-420-37-3061-28-244-153-260-286-217-90-165-204-274-2813894-282-26-14319-29-363-435-393-350-312-2750-20600
   Capital Surplus 
0
0
0
0
0
2,639
217,500
220,360
224,371
340,219
345,166
439,914
444,574
448,095
455,170
460,524
467,168
506,125
528,617
534,838
592,534
597,562
625,017
629,610
781,180
786,763
857,156
861,215
865,726
884,585
923,142
1,092,829
1,101,596
1,109,350
1,119,632
1,072,025
1,082,220
1,091,011
1,098,776
1,136,873
1,153,301
1,165,897
1,327,909
1,333,298
0
0
0
0001,333,2981,327,9091,165,8971,153,3011,136,8731,098,7761,091,0111,082,2201,072,0251,119,6321,109,3501,101,5961,092,829923,142884,585865,726861,215857,156786,763781,180629,610625,017597,562592,534534,838528,617506,125467,168460,524455,170448,095444,574439,914345,166340,219224,371220,360217,5002,63900000
   Treasury Stock00000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
951
0
101,311
2,951
217,850
220,753
224,806
340,582
345,166
439,914
444,574
448,095
455,170
460,524
467,168
506,125
528,617
534,838
592,534
597,562
625,017
629,610
781,180
786,763
857,156
861,215
865,726
884,585
923,142
1,092,829
1,101,596
1,109,350
1,119,632
1,072,025
1,082,220
1,091,011
1,098,776
1,136,873
1,153,301
1,165,897
1,327,909
1,333,298
1,340,218
1,345,535
1,350,981
1,350,9811,345,5351,340,2181,333,2981,327,9091,165,8971,153,3011,136,8731,098,7761,091,0111,082,2201,072,0251,119,6321,109,3501,101,5961,092,829923,142884,585865,726861,215857,156786,763781,180629,610625,017597,562592,534534,838528,617506,125467,168460,524455,170448,095444,574439,914345,166340,582224,806220,753217,8502,951101,311095100



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue146,033
Cost of Revenue-5,472
Gross Profit140,561140,561
 
Operating Income (+$)
Gross Profit140,561
Operating Expense-270,101
Operating Income-129,540-129,540
 
Operating Expense (+$)
Research Development138,220
Selling General Administrative131,881
Selling And Marketing Expenses0
Operating Expense270,101270,101
 
Net Interest Income (+$)
Interest Income9,757
Interest Expense-23,823
Other Finance Cost-323
Net Interest Income-13,743
 
Pretax Income (+$)
Operating Income-129,540
Net Interest Income-13,743
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-142,776-116,304
EBIT - interestExpense = -153,363
-142,776
-119,276
Interest Expense23,823
Earnings Before Interest and Taxes (EBIT)-129,540-118,953
Earnings Before Interest and Taxes (EBITDA)-129,010
 
After tax Income (+$)
Income Before Tax-142,776
Tax Provision-266
Net Income From Continuing Ops-139,768-143,042
Net Income-143,099
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses275,573
Total Other Income/Expenses Net-13,23613,743
 

Technical Analysis of Karyopharm
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Karyopharm. The general trend of Karyopharm is BEARISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Karyopharm's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-14.3%) Bearish trend (14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Karyopharm Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.585 < 1.65 < 1.7.

The bearish price targets are: 1.08 > 0.9881 > 0.9706.

Tweet this
Karyopharm Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Karyopharm Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 6/14.
The longshort score for the Moving Averages is -2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Karyopharm Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Karyopharm Therapeutics Inc. The current macd is -0.04484758.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Karyopharm price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Karyopharm. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Karyopharm price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Karyopharm Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartKaryopharm Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Karyopharm Therapeutics Inc. The current adx is 13.52.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Karyopharm shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Karyopharm Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Karyopharm Therapeutics Inc. The current sar is 1.045444.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Karyopharm Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Karyopharm Therapeutics Inc. The current rsi is 42.06. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Karyopharm Therapeutics Inc Daily Relative Strength Index (RSI) ChartKaryopharm Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Karyopharm Therapeutics Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Karyopharm price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Karyopharm Therapeutics Inc Daily Stochastic Oscillator ChartKaryopharm Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Karyopharm Therapeutics Inc. The current cci is -135.93512675.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Karyopharm Therapeutics Inc Daily Commodity Channel Index (CCI) ChartKaryopharm Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Karyopharm Therapeutics Inc. The current cmo is -21.23595658.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Karyopharm Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartKaryopharm Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Karyopharm Therapeutics Inc. The current willr is -75.6097561.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Karyopharm is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Karyopharm Therapeutics Inc Daily Williams %R ChartKaryopharm Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Karyopharm Therapeutics Inc. The current atr is 0.1472171.

Karyopharm Therapeutics Inc Daily Average True Range (ATR) ChartKaryopharm Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Karyopharm Therapeutics Inc. The current obv is -76,540,297.

Karyopharm Therapeutics Inc Daily On-Balance Volume (OBV) ChartKaryopharm Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Karyopharm Therapeutics Inc. The current mfi is 50.60.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Karyopharm Therapeutics Inc Daily Money Flow Index (MFI) ChartKaryopharm Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Karyopharm Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-08WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-06ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-08MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-09RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-23CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-03CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-10CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-15BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-18SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside

6.3. Candlestick Patterns

Karyopharm Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Karyopharm Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.064
Ma 20Greater thanMa 501.323
Ma 50Greater thanMa 1001.335
Ma 100Greater thanMa 2001.105
OpenGreater thanClose1.170
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Karyopharm with someone you think should read this too:
  • Are you bullish or bearish on Karyopharm? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Karyopharm? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Karyopharm Therapeutics Inc

I send you an email if I find something interesting about Karyopharm Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Karyopharm Therapeutics Inc.

Receive notifications about Karyopharm Therapeutics Inc in your mailbox!